Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Iain McGill
|
| gptkbp:country |
gptkb:United_Kingdom
|
| gptkbp:focusesOn |
gptkb:regulatory_T_cells
gene therapy |
| gptkbp:foundedYear |
2019
|
| gptkbp:founder |
gptkb:James_Douglas
gptkb:John_McCafferty Dominic Schmidt Mark Lowdell Pedro J. Romero Richard M. Griffin |
| gptkbp:fundedBy |
gptkb:Series_B
gptkb:Series_A |
| gptkbp:headquartersLocation |
gptkb:London
|
| https://www.w3.org/2000/01/rdf-schema#label |
Quell Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:therapeuticArea |
transplantation
autoimmune diseases inflammatory diseases |
| gptkbp:website |
https://quelltx.com/
|
| gptkbp:bfsParent |
gptkb:Syncona
gptkb:Parkwalk_Advisors |
| gptkbp:bfsLayer |
7
|